Celcuity Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 155

Employees

  • Stock Symbol
  • CELC

Stock Symbol

  • Share Price
  • $56.31
  • (As of Thursday Closing)

Celcuity General Information

Description

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 16305 36th Avenue North
  • Minneapolis, MN 55446
  • United States
+1 (763)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 16305 36th Avenue North
  • Minneapolis, MN 55446
  • United States
+1 (763)

Celcuity Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Celcuity Stock Performance

As of 19-Nov-2026, Celcuity’s stock price is $56.31. Its current market cap is $2.76B with 48.9M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$56.31 $55.59 $53.54 - $151.02 $2.76B 48.9M 1.25M -$4.71

Celcuity Financials Summary

As of 30-Sep-2026, Celcuity has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,891,406 4,480,462 319,162 270,739
Revenue 0 0 0 0
EBITDA (254,406) (172,025) (113,137) (66,088)
Net Income (256,015) (177,042) (111,779) (63,779)
Total Assets 726,869 466,558 245,123 191,219
Total Debt 755,065 321,905 97,953 37,446
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Celcuity Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Celcuity‘s full profile, request access.

Request a free trial

Celcuity Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its cand
Drug Discovery
Minneapolis, MN
155 As of 2025

Los Angeles, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Celcuity Competitors (2)

One of Celcuity’s 2 competitors is Molecular Express, a Corporation company based in Los Angeles, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Molecular Express Corporation Los Angeles, CA
HiFiBiO Therapeutics Venture Capital-Backed Cambridge, MA
You’re viewing 2 of 2 competitors. Get the full list »

Celcuity Patents

Celcuity Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260053814-A1 Treatment regimens for gedatolisib in hormonally-driven disorders Pending 21-Aug-2024
WO-2026044119-A1 Treatment regimens for gedatolisib in hormonally-driven disorders Pending 21-Aug-2024
AU-2024398904-A1 Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea Pending 12-Dec-2023
EP-4823581-A1 Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea Pending 12-Dec-2023
WO-2025128712-A1 Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea Inactive 12-Dec-2023 A61K31/5377
To view Celcuity’s complete patent history, request access »

Celcuity Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Celcuity Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Celcuity‘s full profile, request access.

Request a free trial

Celcuity ESG

Risk Overview

Risk Rating

Updated November, 08, 2026

37.85 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Celcuity’s complete esg history, request access »

Celcuity FAQs

  • When was Celcuity founded?

    Celcuity was founded in 2012.

  • Where is Celcuity headquartered?

    Celcuity is headquartered in Minneapolis, MN.

  • What is the size of Celcuity?

    Celcuity has 155 total employees.

  • What industry is Celcuity in?

    Celcuity’s primary industry is Drug Discovery.

  • Is Celcuity a private or public company?

    Celcuity is a Public company.

  • What is Celcuity’s stock symbol?

    The ticker symbol for Celcuity is CELC.

  • What is the current stock price of Celcuity?

    As of 19-Nov-2026 the stock price of Celcuity is $56.31.

  • What is the current market cap of Celcuity?

    The current market capitalization of Celcuity is $2.76B.

  • Who are Celcuity’s competitors?

    Molecular Express and HiFiBiO Therapeutics are competitors of Celcuity.

  • What is Celcuity’s annual earnings per share (EPS)?

    Celcuity’s EPS for 12 months was -$4.71.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process